Business, energy, technology, markets and global industry news from Business News Today

Innate Pharma

PharmaDeviceNews Innate Pharma
Innate Pharma’s IPH4502 Phase 1 dose-escalation milestone advances its Nectin-4 exatecan ADC toward a 76-patient year-end readout in advanced solid tumors. Representative image.
Pharma & Biotech

Why Innate Pharma’s 76-patient IPH4502 milestone is only half the Nectin-4 story

Innate Pharma completed IPH4502 dose-escalation enrollment, putting safety, response durability and dose selection at the center of a year-end readout.

Read More
Representative image of lung cancer immunotherapy research as Innate Pharma advances IPH5201 in the MATISSE Phase 2 trial for resectable non-small cell lung cancer at AACR 2026.
Pharma & Biotech

Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis

Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.

Read More